Bliss GVS Pharma Q1 FY27: Profit up 83%, revenue +21%

Q1 FY27 earnings snapshot

Bliss GVS Pharma Limited reported improved profitability for the quarter ended June 30, 2026 (Q1 FY27), publishing unaudited standalone and consolidated financial results. In the narrative summary provided with the update, the company said consolidated net profit rose 83% year-on-year to ₹5.14 crore (₹513.72 lakh). Consolidated revenue from operations for the quarter was reported at ₹29.52 crore (₹2,951.75 lakh), compared with ₹24.29 crore (₹2,429.23 lakh) in the corresponding quarter last year.

Alongside this, the material also includes a separate set of quarterly figures presented in crores, where sales for the quarter ended June 2026 are shown at ₹285.58 crore and net profit at ₹50.10 crore. It also contains a data point stating “consolidated net profit rising 16% year-on-year to ₹501 crore” for the first quarter. These multiple values appear in different parts of the provided content, and readers should treat them as separate reported figures within the same compilation.

What the company reported on profitability

On the consolidated basis (as stated in the text summary), net profit was ₹5.14 crore in Q1 FY27 versus ₹4.44 crore in Q1 FY26. Profit before tax (PBT) was ₹7.55 crore in Q1 FY27 compared with ₹6.31 crore a year earlier. Basic EPS (consolidated) was listed at ₹4.73 versus ₹4.08.

On the standalone basis (as stated in the same summary), net profit was ₹3.86 crore in Q1 FY27 versus ₹2.11 crore in Q1 FY26. Standalone revenue from operations was ₹23.03 crore, up from ₹17.40 crore. Standalone PBT was ₹5.12 crore versus ₹3.06 crore, while basic EPS (standalone) was ₹3.65 compared with ₹2.00.

Revenue growth and operating context

The summary attributes standalone revenue growth to increased sales volumes and market penetration. On the consolidated line items given, revenue from operations increased from ₹24.29 crore to ₹29.52 crore. The same section presents the revenue change as +21% year-on-year.

In another part of the content, a detailed quarterly block states: sales rose 37.65% to ₹285.58 crore in the quarter ended June 2026 compared with ₹207.47 crore in the previous quarter ended June 2025. That block also presents operating margin (OPM) at 26.75% for June 2026 versus 19.92% for June 2025, along with PBDT of ₹85.42 crore and PBT of ₹75.48 crore.

Filing and regulatory disclosures

The company said it published unaudited standalone and consolidated results under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were filed with the National Stock Exchange of India Limited and BSE Limited on August 14, 2026.

The content also states that the board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, following a review by the Audit Committee and statutory auditors.

Consolidated quarter-on-quarter comparison figures included

A separate bullet list in the material provides consolidated revenue from operations for the quarter ended June 30, 2026 at ₹285.58 crore (₹28,557.56 lakh). It also lists a comparison to ₹256.99 crore (₹25,699.32 lakh) in the previous quarter and ₹207.47 crore (₹20,746.92 lakh) year-on-year.

For profitability, the same section lists consolidated net profit of ₹43.04 crore (₹4,303.79 lakh), compared with ₹44.92 crore (₹4,492.33 lakh) in the previous quarter and ₹35.58 crore (₹3,557.51 lakh) year-on-year. Total comprehensive income for the quarter was given as ₹48.89 crore (₹4,889.00 lakh), compared with ₹47.92 crore (₹4,791.80 lakh) in the previous quarter and ₹33.13 crore (₹3,313.42 lakh) year-on-year. Basic and diluted EPS were shown at ₹4.08 and ₹4.04, respectively.

Key numbers at a glance (normalized to ₹ crore)

Stock reaction and recent shareholder returns

The content notes the stock price moved down 3.27% from its previous close of ₹493.65, with the last traded price stated at ₹477.55. It also mentions that in the quarter ending March 2026, the company declared a dividend of ₹1.00 per share on May 12, 2026, translating to a dividend yield of 0.31%.

These data points provide immediate context for how market participants and income-focused shareholders might frame the quarter, alongside the operational and earnings numbers presented.

Additional historical metrics cited in the material

The document also includes broader metrics based on consolidated financials: annual revenue growth of 18.25% versus a 3-year CAGR of 9.06%. It states the company spent 1.3% of operating revenues on interest expenses and 14.72% toward employee cost in the year ending March 31, 2026.

Separately, it lists a full-year figure: “For the full year FY2026–2027, revenue reached ₹1,000.64 crore and profit touched ₹134.73 crore.” This appears as a standalone statement within the provided text.

Why this update matters for investors tracking pharma earnings

The primary takeaway from the compiled release is that Bliss GVS Pharma’s Q1 FY27 update contains multiple layers of financial disclosure, including summary headline figures and detailed quarterly tables. Across these sections, revenue and profit are shown rising on year-on-year comparisons, while the quarter-on-quarter comparisons cited in the consolidated bullet list show revenue higher but net profit lower versus the immediate preceding quarter.

For investors, the filing date (August 14, 2026) and the fact that the numbers are unaudited are important context points. The inclusion of both standalone and consolidated data also helps distinguish performance at the parent level from the group level.

Conclusion

Bliss GVS Pharma’s Q1 FY27 disclosure, filed with NSE and BSE on August 14, 2026, reported higher revenue and profit in the quarter ended June 30, 2026, with multiple data presentations included in the material. The next step for readers is to track subsequent company communications and quarterly filings for consistent line-item comparisons across periods.